ScripFour Chinese drug developers have snagged domestic approvals for first-in-class therapies, following on from a similar feat by two of their compatriot companies earlier this year. On July 2, BeBette
ScripWhile the world’s pharma industry has increasingly connected with Chinese-developed me-too or fast-follower novel drugs over the past few years, AstraZeneca, which already has more than three decades
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regeneron Bolsters Ophthalmic Portfoli
In VivoThe 2023 pharmaceutical sales ranking of the top 100 Asian biopharma firms reveals a mix of company-specific and wider performance factors linked to both individual corporate fortunes and the changing